TCBP News and Press, TC BioPharm (Holdings) plc From 03/09/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine! It’s time for another breakdown of the biggest pre-market stock movers as we prepare for the opening bell on Wednesday! Source: f11photo/Shutterstock.com News moving stocks this morning includ...

On Tuesday, TC Biopharm (NASDAQ:TCBP), a U.K.-based clinical-stage biotech, announced interim data from its Phase 1a/2b trial for TCB-002, OmnImmune in relapse/ refractory acute myeloid leukemia ("AML"). An experimental allogeneic cell therapy OmnImmune contains unmodified gamma delta T cells...

TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells -Complete and near complete responses (morphologic leukemia-free state) observed with OmnImmune® starting at lowest dose level in Phase ...

TC Biopharm to Host Corporate Update Call on March 8th PR Newswire EDINBURGH, Scotland , March 2, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developi...

TC Biopharm (NASDAQ: TCBP) , a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced that it has closed on a previously announced initial public offering. The offering comprised more than 4 million A...

TC Biopharm Announces Appointment of New Board Members PR Newswire EDINBURGH, Scotland , Feb. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developi...